Vixtimotamab  (Synonyms: AMV-564; TandAb T564)

Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML)^[1].

Human; Chimeric

KD: 0.3 nM (CD33, HL-60 cells), 5.1 nM (CD3, Human T cells)^[1]

Vixtimotamab (TandAb T564; 24 h) 诱导 CD25 和 CD69, EC₅₀ 分别为 1 pM 和 2 pM^[1]。
Vixtimotamab (TandAb T564; 4 days) 诱导 PBMCs 中的 T 细胞增殖，EC₅₀ 为 3 pM^[1]。
Vixtimotamab (TandAb T564; 25 pM, 48 h) 显示对 HL-60 和 KG-1a 细胞的细胞毒性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5 days) 在预防性 HL-60 移植 NOD/scid 小鼠模型中显示剂量依赖性肿瘤生长延迟^[1]。
Vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) 在建立的 HL-60 移植 NOD/scid 小鼠模型中显著抑制肿瘤生长^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [V-kappa-VH-V-lambda-VH']-noncovalent dimer (tandem diabody)

• 
  Immobilized Vixtimotamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC₅₀ for this effect is 4.95 ng/mL.
• 
  Immobilized Vixtimotamab can bind Human Siglec-3/CD33 Protein (ECD, His Tag). The EC₅₀ for this effect is 4.95 ng/mL.

• [1]. Reusch U, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2016 Dec 1;22(23):5829-5838.  [Content Brief]